Haoyu Pan, Zetao Ding, Zhixia Yang, Zihan Tang, Lei Li, Jialin Teng, Yue Sun, Honglei Liu, Xiaobing Cheng, Yutong Su, Junna Ye, Qiongyi Hu, Huihui Chi, Zhuochao Zhou, Jianfen Meng, Binshen Ouyang, Yunpeng Zhu, Haoyi Yao, Jian Li, Tingting Liu, Chengde Yang, Hui Shi
Valvular heart disease (VHD) is a prevalent cardiac manifestation in antiphospholipid syndrome (APS) patients. However, risk factors and predictors for antiphospholipid antibody-associated VHD (aPL-VHD) remain vague. We aimed to assess the risk of developing aPL-VHD in aPL-positive patients, by establishing a clinical prediction model upon a cross-sectional cohort from APS-Shanghai database, including 383 APS patients and durable aPL carriers with transthoracic echocardiography investigation. The prevalence of aPL-VHD was 11...
November 2023: Clinical Immunology: the Official Journal of the Clinical Immunology Society